ACHIEVEMENT OF GLYCAEMIC TARGETS WITH CANAGLIFLOZIN IN TRIPLE THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)

被引：0
|
作者：
Diels, J. [1 ]
Schubert, A. [2 ]
Hamilton, G. [3 ]
Canovatchel, W. [4 ]
机构：
[1] Janssen Res & Dev, Beerse, Belgium
[2] Janssen Cilag Poland, Warsaw, Poland
[3] Janssen Cilag Ltd, High Wycombe, Bucks, England
[4] Janssen Global Serv LLC, Raritan, NJ USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2048
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB8
引用
收藏
页码：A598 / A598
页数：1
相关论文
共 50 条
  • [41] Pregnancy outcomes in women with Type 2 diabetes mellitus (T2DM)
    Tan, Z.
    Pang, W. H.
    Todd, D.
    Halliday, M.
    Gill, F.
    Rhoads, M.
    Sathiskumar, P.
    Gallagher, A.
    de Chazal, R.
    Lawrence, I. G.
    [J]. DIABETIC MEDICINE, 2008, 25
  • [42] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS SITAGLIPTIN AS THIRD-LINE THERAPY IN TYPE 2 DIABETES MELLITUS (T2DM) IN A CANADIAN SETTING
    Sabapathy, S.
    Neslusan, C.
    Yoong, K.
    Teschemaker, A. R.
    Johansen, P.
    Willis, M.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A61 - A61
  • [43] Gut microbiota influence in type 2 diabetes mellitus (T2DM)
    Cunningham, A. L.
    Stephens, J. W.
    Harris, D. A.
    [J]. GUT PATHOGENS, 2021, 13 (01)
  • [44] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS LIRAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES (T2DM) FAILING TO ACHIEVE GLYCAEMIC CONTROL ON METFORMIN MONOTHERAPY IN IRELAND
    Bacon, T.
    Willis, M.
    Johansen, P.
    Neslusan, C.
    Nuhoho, S.
    Worbes-Cerezo, M.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A345 - A345
  • [45] Graft of Microencapsulated Sertoli Cells for the Cell Therapy of Type 2 Diabetes Mellitus (T2DM)
    Luca, Giovanni
    Mancuso, Francesca
    Calvitti, Mario
    Arato, Iva
    Falabella, Giulia
    Bobo, Mariella
    Beccetti, Ennio
    Calafiore, Riccardo
    [J]. TRANSPLANTATION, 2013, 96 (06) : S116 - S116
  • [46] Colesevelam HCl improves glycaemic control in patients with type 2 diabetes (T2DM): a pilot study
    Jones, M.
    Schwartz, S.
    Zieve, F.
    Kalin, M.
    [J]. DIABETOLOGIA, 2006, 49 : 746 - 747
  • [47] Long-term Efficacy and Safety of Canagliflozin (CANA) in Older Patients with Type 2 Diabetes Mellitus (T2DM) Over 104 Weeks
    Bode, Bruce
    Stenlof, Kaj
    Harris, Stewart
    Sullivan, Daniel
    Fung, Albert
    Usiskin, Keith
    [J]. DIABETES, 2014, 63 : A71 - A71
  • [48] Real-World (RW) Glycemic Control and Medication Adherence among Patients with Type 2 Diabetes Mellitus (T2DM) Initiated on Canagliflozin
    Jain, Rahul
    Cai, Jennifer
    Fu, An-Chen
    Chow, Wing
    Tan, Hiangkiat
    [J]. DIABETES, 2016, 65 : A304 - A305
  • [49] Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on Sulfonylurea (SU) Monotherapy: A CANVAS Substudy
    Fulcher, Greg
    Matthews, David
    Perkovic, Vlado
    Mahaffey, Kenneth W.
    Weiss, Robert
    Rosenstock, Julio
    Capuano, George
    Desai, Mehul
    Shaw, Wayne
    Vercruysse, Frank
    Meininger, Gary
    Neal, Bruce
    [J]. DIABETES, 2013, 62 : A292 - A292
  • [50] SHORT-TERM ECONOMIC AND CLINICAL OUTCOMES OF CANAGLIFLOZIN COMPARED TO SITAGLIPTIN IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS (T2DM)
    Lopez, J. M.
    Martin, S.
    Ektare, V
    Patel, D.
    Rupnow, M. F.
    Botteman, M. F.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A251 - A251
12345